Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Yixin Pfister-Fu has worked on the following 12 EPO patent applications which have been published in the last five years:

EP11702096

USE OF AN ADRENAL HORMONE-MODIFYING AGENT

IPC classification:
A61K 31/4188, A61K 31/55, A61P 5/00
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13701194

NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR

IPC classification:
A61K 31/407, A61P 5/38, C07D 487/04
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13712589

FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS

IPC classification:
A61K 31/506, A61P 19/08
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13718671

TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE

IPC classification:
A61K 31/5025, A61K 31/506, A61K 31/53, A61K 45/06
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13720275

COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS

IPC classification:
A61K 31/4164, A61K 38/31, A61P 5/00
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15155712

Antibody formulations

IPC classification:
A61K 9/00, A61K 39/395, C07K 16/00, C07K 16/28
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
The patent has been granted
EP12891015

PRESSURE RESPONSIVE DOWNHOLE TOOL HAVING A SELECTIVELY ACTIVATABLE PRESSURE RELIEF VALVE AND RELATED METHODS

IPC classification:
E21B 34/06, E21B 34/08
Applicant:
Halliburton Energy Services, Inc.
Agent:
Hoffmann Eitle PartmbB
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12734212

NOVEL USES

IPC classification:
A61K 39/395
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13857873

NOVEL PHARMACEUTICAL COMPOSITION

IPC classification:
A61K 9/14, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13858515

COMBINATION

IPC classification:
A61K 9/20, A61P 35/00, C07D 231/38
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14730592

COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER

IPC classification:
A61K 31/4439, A61K 31/506, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14819084

PHARMACEUTICAL DOSAGE FORMS

IPC classification:
A61K 9/16, A61K 9/48, A61K 31/506
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature